(fra kommisjonsbeslutningen)

(1) Metofluthrin was included in Annex I to Directive 98/8/EC of the European Parliament and of the Council as an active substance for use in biocidal products of product-type 18. Pursuant to Article 86 of Regulation (EU) No 528/2012, it was therefore considered approved until 30 April 2021 under that Regulation subject to the conditions set out in Annex I to Directive 98/8/EC. 

(2) On 25 October 2019, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of the approval of metofluthrin for use in biocidal products of product-type 18 (‘the application’). The application was evaluated by the competent authority of Ireland. 

(3) Pursuant to Commission Implementing Decision (EU) 2021/327, the expiry date of approval of metofluthrin for use in biocidal products of product-type 18 was postponed to 31 October 2023. That expiry date was further postponed to 31 October 2024 by Commission Implementing Decision (EU) 2023/1086, and to 30 April 2026 by Commission Implementing Decision (EU) 2024/24605 in order to allow sufficient time for the examination of the application.

(4) Commission Implementing Regulation (EU) [Publication office please add here the number of this Regulation C(2025) 1350 once it is associated, along the whole Decision] renewed the approval of metofluthrin (renamed to epsilon-metofluthrin) for use in biocidal products of product-type 18, subject to the conditions in the Annex to that Regulation, including the expiry date of approval. Therefore, it is appropriate to repeal Implementing Decision (EU) 2024/2460 postponing the initial expiry date of the approval of metofluthrin,